Drug intelligence / Profile preview

LTC004 + MIL-97

Development stage: Unknown
Lead developer: Letolab
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

LTC004 + MIL-97 is an experimental combination therapy under investigation for advanced or metastatic pancreatic cancer and other solid tumors. LTC004 is a modified recombinant form of human interleukin-2 (IL-2), designed to enhance immunoregulatory and antineoplastic activities by stimulating immune cell proliferation and activation[4][7]. MIL-97 is a CD40 agonist antibody that activates the CD40 pathway on antigen-presenting cells, promoting anti-tumor immune responses[2]. The combination aims to synergistically boost anti-tumor immunity by activating both T cells (via IL-2) and antigen-presenting cells (via CD40 agonism). Clinical trials are ongoing to assess safety, tolerability, pharmacokinetics, and efficacy in patients with advanced or metastatic pancreatic cancer[1][2].

Other names: LTC-004LTC004LTC 004MIL97MIL-97MIL 97

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)CD40 (Cluster of differentiation 40 receptor)

Beyond the preview

Go deeper on LTC004 + MIL-97.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTC004 + MIL-97.

Explore the full profile